Short, sourced news briefs on the peptide supply chain, covering product launches, manufacturing facilities and raw-material capacity. Each item notes what the source did not disclose, such as capacity, pricing or orders.

BioCompounding publishes long-form equity research on medtech and biopharma companies, including earnings reviews and company deep dives. It also explains industry structure, such as how generics and biosimilars differ as businesses.

Penwood is an essay newsletter by a commercial leader who advises biopharma and MedTech companies on launch strategy and AI adoption. Each issue argues a specific point, such as why launches miss forecasts, why commercial teams stall on AI, or why connected-device data decisions belong before regulatory clearance, backed by industry studies and the author's experience at Novartis and Sanofi.

A daily-style biopharma newsletter offering commentary on therapeutics, regulatory oversight and clinical trials, organised around weekday themes. Readers get a short, opinionated take on industry developments such as biosimilar choices, regulator priorities and upcoming conference data.